AstraZeneca inks deal with Japanese biotech JCR in CNS indication
AstraZeneca and its rare disease unit Alexion are doing a deal with JCR Pharmaceuticals, which will see them use JCR’s technology to try to develop …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
